Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Adults 65 years and older (seniors) experience more complications following influenza infection than younger adults. We estimated the relative vaccine effectiveness (rVE) of a trivalent high dose (HD-IIV3) versus an adjuvanted trivalent influenza vaccine (aIIV3) in seniors for respiratory-related hospitalizations.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vaccine

Title: Vaccine

Publisher: Elsevier BV

ISSN (Electronic): 1873-2518

ISSN (Print): 0264-410X

Publication date (Electronic): January 10 2020

Volume: 38

Issue: 2

Affiliations

[1 ] Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Vaccine Epidemiology and Modelling, Sanofi Pasteur, Swiftwater, PA, USA. Electronic address: rob.vanaalst@sanofi.com.

[2 ] Brown University, School of Public Health, Dept. Health Services, Policy and Practice, USA; Providence VA Medical Center, Center of Long-Term Services and Support, USA; Center for Gerontology & Healthcare Research, Providence, RI, USA; Warren Alpert Medical School of Brown University, Providence, RI, USA.

[3 ] Brown University, School of Public Health, Dept. Health Services, Policy and Practice, USA; Providence VA Medical Center, Center of Long-Term Services and Support, USA.

[4 ] Department of Community Health Sciences, College of Medicine, University of Manitoba, Winnipeg, MB, Canada; George & Fay Yee Center for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, MB, Canada.

[5 ] Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

[6 ] Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Unit of PharmacoTherapy, -Epidemiology & -Economics (PTE2), University of Groningen, Department of Pharmacy, Groningen, the Netherlands; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, the Netherlands.

[7 ] Vaccine Epidemiology and Modelling, Sanofi Pasteur, Swiftwater, PA, USA; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

Article

Publisher Item ID: S0264-410X(19)31349-0

DOI: 10.1016/j.vaccine.2019.09.105

PubMed ID: 31606249

SO-VID: 712e4e7e-157b-40e5-b442-0c5ace0fd2fc

History

Keywords: High-dose,Adjuvanted,Comparative effectiveness,HD-IIV3,Influenza vaccine,PERR,Previous event rate ratio,Relative vaccine effectiveness,Residual confounding,Unmeasured confounding factors,aIIV3,rVE

Data availability:

Keywords: High-dose, Adjuvanted, Comparative effectiveness, HD-IIV3, Influenza vaccine, PERR, Previous event rate ratio, Relative vaccine effectiveness, Residual confounding, Unmeasured confounding factors, aIIV3, rVE

Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.

Read this article at

Abstract

Related collections

Malaria vaccine development

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 280

Cited by 33